These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 16932346)

  • 41. Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia.
    Ma W; Tseng R; Gorre M; Jilani I; Keating M; Kantarjian H; Cortes J; O'Brien S; Giles F; Albitar M
    Haematologica; 2007 Feb; 92(2):170-5. PubMed ID: 17296565
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR.
    Pelz-Ackermann O; Cross M; Pfeifer H; Deininger M; Wang SY; Al-Ali HK; Niederwieser D; Lange T
    Leukemia; 2008 Dec; 22(12):2288-91. PubMed ID: 18615107
    [No Abstract]   [Full Text] [Related]  

  • 43. Reliability of Cell-Free DNA and Targeted NGS in Predicting Chromosomal Abnormalities of Patients With Myeloid Neoplasms.
    Ip A; Della Pia A; Kim GYG; Lofters J; Behrmann J; Patel D; Kats S; Estella JJ; De Dios I; Ma W; Pecora AL; Goy AH; Koprivnikar J; McCloskey JK; Albitar M
    Front Oncol; 2022; 12():923809. PubMed ID: 35774119
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients.
    Elias MH; Baba AA; Husin A; Abdullah AD; Hassan R; Sim GA; Wahid SF; Ankathil R
    Hematol Rep; 2012 Nov; 4(4):e23. PubMed ID: 23355941
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance.
    Ma W; Kantarjian H; Zhang X; Wang X; Estrov Z; O'Brien S; Albitar M
    Leuk Res; 2011 Apr; 35(4):526-33. PubMed ID: 20951430
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.
    Ma W; Kantarjian H; Bekele B; Donahue AC; Zhang X; Zhang ZJ; O'Brien S; Estey E; Estrov Z; Cortes J; Keating M; Giles F; Albitar M
    Clin Cancer Res; 2009 Jun; 15(11):3820-6. PubMed ID: 19458051
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.
    von Bubnoff N; Peschel C; Duyster J
    Leukemia; 2003 May; 17(5):829-38. PubMed ID: 12750693
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The differences and correlations of BCR-ABL transcripts between peripheral blood and bone marrow assays are associated with the molecular responses in the bone marrow for chronic myelogenous leukemia.
    Jiang Q; Zhao XY; Qin YZ; Liu YR; Lai YY; Jiang B; Huang XJ
    Am J Hematol; 2012 Dec; 87(12):1065-9. PubMed ID: 22965919
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
    Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib.
    Reinhold U; Hennig E; Leiblein S; Niederwieser D; Deininger MW
    Leukemia; 2003 Oct; 17(10):1925-9. PubMed ID: 14513039
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA.
    Ma W; Kantarjian H; Jilani I; Gorre M; Bhalla K; Ottmann O; Giles F; Albitar M
    Leukemia; 2006 Nov; 20(11):1989-91. PubMed ID: 16932346
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
    Tanaka R; Kimura S
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.